Dupilumab Treatment in Pediatric Patients Aged 6–11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review

Michael J Cork,1,2 Simon G Danby,1,2 Ana B Rossi,3 Ashish Bansal4 1Sheffield Dermatology Research, University of Sheffield, Sheffield, UK; 2Sheffield Children’s Hospital, Sheffield, UK; 3Sanofi, Cambridge, MA, USA; 4Regeneron Pharmaceuticals Inc., Tarrytown, NY, USACorrespondence: Michael J Cork, Sheffield Dermatology Research, Department of Infection and Immunity, The University of Sheffield, K Floor, The Medical School (RHH tower), Beech Hill, Sheffield, S10 2RX, UK, Email m.j.cork@sheffield.ac.ukAbstract: Atopic dermatitis (AD) is the most common inflammatory skin disease in children. Children with severe AD have a multidimensional disease burden characterized by skin lesions, itching, frequent infections, sleep deprivation, and a high rate of comorbidities. These impact the mental health and overall quality of life of not only the children but also of their parents and caregivers. There are few effective available treatment options for young children with severe AD that are suitable for long-term use. Due to their adverse effects, practice guidelines consider systemic agents inappropriate for this age group, although they are still used off-label in extreme cases. The biologic dupilumab has recently been approved for children aged 6– 11 years with severe (EU) and moderate-to-severe (USA) AD, offering hope to this population of patients with a high unmet clinical need. The purpose of this review is to describe the unmet needs of AD patients aged 6– 11 years prior to dupilumab approval and to summarize existing clinical data supporting dupilumab’s safety and efficacy in these children.Keywords: atopic dermatitis, children, dupilumab, pediatric, severe